Nicollas Nunes Rabelo

Dr. Nicollas Nunes Rabelo


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2020 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
JFJosé Luiz de Faria
José Luiz de Faria
JBJosué da Silva Brito
Josué da Silva Brito
LSLouise Teixeira Costa e Silva
Louise Teixeira Costa e Silva
CKChristiano Tadeu Sanches Mattos Kilesse
Christiano Tadeu Sanches Mattos Kilesse
NSNicolli Bellotti de Souza
Nicolli Bellotti de Souza
NRNicollas Nunes Rabelo
Nicollas Nunes Rabelo

23 September 2020 in British Journal Of Neurosurgery
Verified
Journal Article
Closed access
CSCarlos Michell Tôrres Santos
Carlos Michell Tôrres Santos
CPCarlos Umberto Pereira
Carlos Umberto Pereira
PCPedro Henrique Silveira Chaves
Pedro Henrique Silveira Chaves
PTPábula Thais Rodrigues de Lima Tôrres
Pábula Thais Rodrigues de Lima Tôrres
DODébora Moura da Paixão Oliveira
Débora Moura da Paixão Oliveira
NRNicollas Nunes Rabelo
Nicollas Nunes Rabelo
The physical processes of incision, traction and hemostasis used for craniotomy, stimulate nerve fibers and specific nociceptors, resulting in postoperative pain. During the first 24 h after craniotomy, 87% of patients have postoperatory pain. The rate of suffering pain after craniotomy falls 3% for every year of life. The objective of this study is to review the available therapeutic options to help physicians treating this pain, and discuss pain mechanisms, pathophysiology, plasticity, risk factors and psychological factors. This is a narrative review of the literature from 1970 to June 2019. Data were collected by doing a search in PubMed, EMBASE, Cochrane Reviews and a manual search of all relevant literature references. The literature includes some drugs treatment: Opioids, codeine, morphine, and tramadol, anti-inflammatory non-steroids such as cyclooxygenase-2 inhibitors, gabapentin. It discusses: side effects, pharmacodynamics and indications of each drug, anatomy and Inervation of Skull and its Linigs, pathogenesis of pain Post-craniotomy, scalp nerve block, surgical nerve injury, neuronal plasticity, surgical factors and chronic post-surgical pain.

1 June 2014 in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
Verified
Journal Article
Open access
PDF file
DRDiogo Gontijo Dos Reis
Diogo Gontijo Dos Reis
NRNicollas Nunes Rabelo
Nicollas Nunes Rabelo
SASidnei Jose Aratake
Sidnei Jose Aratake

20 December 2023 in Neurosurgery
Verified
Journal Article
Closed access
LBLeonardo de Barros Oliveira Brenner
Leonardo de Barros Oliveira Brenner
FHFernando Hakim
Fernando Hakim
GSGabriel da Silva Semione
Gabriel da Silva Semione
Raphael BertaniRaphael Bertani
Raphael Bertani
SBSávio Batista
Sávio Batista
EFEberval Gadelha Figueiredo
Eberval Gadelha Figueiredo
BACKGROUND AND OBJECTIVES: Ventriculoperitoneal shunt (VPS) is usually the primary choice for cerebrospinal fluid shunting for most neurosurgeons, while ventriculoatrial shunt (VAS) is a second-line procedure because of historical complications. Remarkably, there is no robust evidence claiming the superiority of VPS over VAS. Thus, we aimed to compare both procedures through a meta-analysis. METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, the authors systematically searched the literature for articles comparing VAS with VPS. The included articles had to detail one of the following outcomes: revisions, infections, shunt-related mortality, or complications. In addition, the cohort for each shunt model had to encompass more than 4 patients. RESULTS: Of 1872 articles, 16 met our criteria, involving 4304 patients, with 1619 undergoing VAS and 2685 receiving VPS placement. Analysis of revision surgeries showed no significant difference between VAS and VPS (risk ratio [RR] = 1.10, 95% CI: 0.9-1.34; I 2 = 84%, random effects). Regarding infections, the analysis also found no significant difference between the groups (RR = 0.67, 95% CI: 0.36-1.25; I 2 = 74%, random effects). There was no statistically significant disparity between both methods concerning shunt-related deaths (RR = 2.11, 95% CI: 0.68-6.60; I 2 = 56%, random effects). Included studies after 2000 showed no VAS led to cardiopulmonary complications, and only 1 shunt-related death could be identified. CONCLUSION: Both methods show no significant differences in procedure revisions, infections, and shunt-related mortality. The literature is outdated, research in adults is lacking, and future randomized studies are crucial to understand the profile of VAS when comparing it with VPS. The final decision on which distal site for cerebrospinal shunting to use should be based on the patient's characteristics and the surgeon's expertise.

9 July 2019 in Trials
Verified
Journal Article
Open access
PDF file
BCBruno Braga Sisnando da Costa
Bruno Braga Sisnando da Costa
IWIsabela Costola Windlin
Isabela Costola Windlin
EKEdwin Koterba
Edwin Koterba
VYVitor Nagai Yamaki
Vitor Nagai Yamaki
NRNicollas Nunes Rabelo
Nicollas Nunes Rabelo
EFEberval Gadelha Figueiredo
Eberval Gadelha Figueiredo
Recent findings on the benefits of glibenclamide as a neuroprotective drug have started a new era for prospective studies on sulfonylureas. The effect of glibenclamide blocking the Sur1-Trpm4 channel was examined in models of subarachnoid hemorrhage and stroke, with findings of significantly reduced tight-junction abnormalities, resulting in less edema formation and considerably reduced transsynaptic apoptosis of hippocampal neurons and significantly ameliorated impairments in spatial learning. Based on these data, we plan a clinical trial to establish evidence of glibenclamide as an adjunct treatment in aneurysmal subarachnoid hemorrhage. An estimated 80 patients meeting the inclusion criteria of radiological confirmatory evidence of an aneurysmal subarachnoid hemorrhage, age 18–70 years, and presentation of less than 96 h from the ictus will be allocated randomly into two groups, one receiving 5 mg daily oral intake of glibenclamide for 21 days and another control group receiving a placebo. The study’s primary outcome is the modified Rankin scale (mRS) after 6 months, as favorable (mRS 0–2) or unfavorable (mRS 3–6). The secondary outcomes will be late cognitive status, assessed after 6 months by psychological tests (the Short Form Health Survey Questionnaire and the Montreal Cognitive Assessment), as well as death at 6 months, delayed cerebral ischemia and occurrence of serious adverse events due to study medication. There is a growing interest in the scientific community regarding glibenclamide in brain edema and traumatic brain injury, but with very little of this interest targeting spontaneous brain hemorrhage, especially aneurism rupture. Positive outcomes are expected for the treatment patients, especially in language and memory preservation, as has been shown in experimental models. ClinicalTrials.gov, NCT03569540 . Retrospectively registered on 26 June 2018.

1 July 2020 in World Neurosurgery
Verified
Journal Article
Closed access
GCGiselle Coelho
Giselle Coelho
EFEberval Gadelha Figueiredo
Eberval Gadelha Figueiredo
NRNicollas Nunes Rabelo
Nicollas Nunes Rabelo
MSMatheus Rodrigues de Souza
Matheus Rodrigues de Souza
CFCaroline Ferreira Fagundes
Caroline Ferreira Fagundes
NZNelci Zanon
Nelci Zanon